RAPT Therapeutics Inc. (RAPT)
1.10
-0.01 (-0.90%)
At close: Apr 04, 2025, 11:00 AM
-0.90% (1D)
| Bid | 1.08 |
| Market Cap | 145.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.19 |
| PE Ratio (ttm) | -0.34 |
| Forward PE | -0.57 |
| Analyst | Hold |
| Ask | 1.34 |
| Volume | 234,336 |
| Avg. Volume (20D) | 864,004 |
| Open | 1.11 |
| Previous Close | 1.11 |
| Day's Range | 1.04 - 1.11 |
| 52-Week Range | 0.79 - 9.65 |
| Beta | -0.29 |
About RAPT
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead onco...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 31, 2019
Employees 68
Stock Exchange NASDAQ
Ticker Symbol RAPT
Website https://www.rapt.com
Analyst Forecast
According to 7 analyst ratings, the average rating for RAPT stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 263.64% from the latest price.
Stock Forecasts3 months ago
+110.81%
RAPT Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
4 months ago
-39.45%
RAPT Therapeutics shares are trading lower after the company terminated its Zelnecirnon program following an FDA clinical hold due to a severe adverse event involving liver injury.
